



Senno Therapeutics Establishes New R&D Site at SakuLab-Tsukuba

July 1th, 2026

Senno Therapeutics, Inc. (Tokyo, Japan; CEO: Chieko Mori; “Senno”), a biotechnology company developing innovative cell therapies based on proprietary allogeneic iPSC-derived hepatoblasts, today announced that it has established a new research and development site at SakuLab-Tsukuba, a life sciences incubation facility operated by Astellas Pharma Inc..

SakuLab-Tsukuba is an innovation hub equipped with state-of-the-art laboratory facilities and shared research infrastructure, bringing together startups and research organizations in the life sciences and biotechnology sectors. By leveraging this environment, Senno will further strengthen its research capabilities and accelerate the development of its lead pipeline candidate, SEN-001, as well as the discovery and development of additional innovative regenerative medicine products.

Senno also aims to foster open innovation through active collaboration and knowledge exchange with resident companies, academic institutions, and supporting organizations within the SakuLab-Tsukuba ecosystem, thereby expanding opportunities for scientific and technological advancement. Senno remains committed to delivering new therapeutic options for patients with diseases that currently lack effective treatments by advancing regenerative medicine technologies toward clinical application.

Location:

Tsukuba Research Center, Astellas Pharma Inc.

27 Miyukigaoka, Tsukuba, Ibaraki 305-8585, Japan

About SEN-001 (Allogeneic iPSC-derived Hepatoblasts)

SEN-001 is a cell therapy based on hepatoblasts differentiated from allogeneic iPSCs. Hepatoblasts are liver progenitor cells capable of differentiating into hepatocytes. Following administration, SEN-001 is expected to engraft in the liver, proliferate, and contribute to the restoration of liver function.

The platform enables large-scale manufacturing while maintaining cell consistency and supports cryopreservation, allowing for an off-the-shelf therapeutic approach with scalable and reliable supply.

About Acute-on-chronic liver failure (ACLF)

ACLF is a severe condition in which patients with chronic liver disease, such as cirrhosis, experience rapid deterioration of liver function triggered by factors including infection or alcohol consumption, often leading to multi-organ failure. It has been reported that the 28-day mortality rate reaches 30–40%, indicating a high short-term risk of death.

While the number of patients is increasing globally, liver transplantation remains the only curative treatment option. However, due to donor shortages and other limitations, there is a strong need for the development of alternative therapeutic approaches.

About Senno Therapeutics

Senno Therapeutics is a biotechnology company developing regenerative therapies for severe liver diseases using allogeneic iPSC-derived hepatoblasts. Founded in 2024 and based in Tokyo, the company builds on research originating from the University of Tokyo.

Website: <https://sennotx.com/>
